Sapporo Clinical Laboratory Center, Inc. (9776) AI Stock Analysis

• Market Cap: ¥3.94B
• Dividend Yield: 2.05%
• Average Volume (3M): 2.08K
• Price to Earnings (P/E): 7.9
• Beta (1Y): 0.28
• Revenue Growth: 2.23%
• EPS Growth: 12.02%
• Country: JP
• Employees: 871
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 31.13
• Shares Outstanding: 4,216,000
• 10 Day Avg. Volume: 600
• 30 Day Avg. Volume: 2,076
• PEG Ratio: 0.22
• Price to Book (P/B): 0.27
• Price to Sales (P/S): 0.15
• P/FCF Ratio: -6.24
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 82 Outperform
• Price Target: ¥1,369.00 ▲(22.01% Upside)

Sapporo Clinical Laboratory Center, Inc. is well-positioned with strong financial performance, robust technical indicators, and attractive valuation metrics. The company's solid revenue growth and operational efficiency, combined with a bullish market trend and low P/E ratio, make it a compelling investment opportunity.

Sapporo Clinical Laboratory Center, Inc. Business Overview & Revenue Model

Company Description

Sapporo Clinical Laboratory Center, Inc. (9776) is a leading provider of clinical laboratory services in Japan, specializing in a wide range of diagnostic testing and health monitoring solutions. The company operates in the healthcare sector, focusing on delivering accurate and timely laboratory results to hospitals, clinics, and other healthcare facilities. Its core services include blood testing, microbiology, pathology, and genetic testing, catering to both routine and specialized diagnostic needs.

How the Company Makes Money

The company generates revenue primarily through its extensive portfolio of laboratory testing services, billing healthcare providers and patients for tests performed. Key revenue streams include fees for individual tests, subscription models for regular health monitoring services, and contracts with hospitals and clinics for routine testing services. Additionally, Sapporo Clinical Laboratory Center may engage in partnerships with pharmaceutical companies for clinical trials, which can provide supplementary income. The company also benefits from government and insurance reimbursements for eligible laboratory services, contributing significantly to its earnings.

Sapporo Clinical Laboratory Center, Inc. Financial Statement Overview

Summary

Sapporo Clinical Laboratory Center, Inc. exhibits a strong financial profile with consistent revenue growth and solid operational efficiency. The balance sheet is robust, indicating financial stability and prudent leverage. However, attention to capital expenditures is needed to enhance free cash flow sustainability.

Income Statement

Sapporo Clinical Laboratory Center, Inc. has demonstrated consistent revenue growth over the years, with a notable increase in EBIT and EBITDA margins, indicating solid operational efficiency. However, the net profit margin has fluctuated, reflecting some challenges in cost management or external factors impacting net income.

Balance Sheet

The company maintains a strong equity position with a favorable debt-to-equity ratio, indicating prudent financial leverage. The equity ratio is robust, showcasing stability and a solid asset base. Return on Equity has been stable, suggesting effective use of shareholder funds.

Cash Flow

Operating cash flows remain positive, yet there is volatility in free cash flow due to high capital expenditures. The company has shown resilience in generating cash flow from operations, but consistent negative free cash flow suggests the need for careful capital management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	20.20B	20.13B	19.68B	20.13B	19.11B	17.50B
Gross Profit	6.17B	6.14B	5.90B	6.30B	6.32B	5.73B
EBITDA	1.29B	1.27B	1.14B	1.49B	2.06B	1.45B
Net Income	455.83M	464.18M	380.16M	568.62M	1.04B	793.69M
Balance Sheet
Total Assets	16.77B	16.45B	16.68B	16.52B	16.15B	14.51B
Cash, Cash Equivalents and Short-Term Investments	3.11B	2.94B	3.98B	3.66B	2.99B	2.36B
Total Debt	1.90B	1.93B	2.20B	2.43B	2.58B	2.10B
Total Liabilities	5.38B	5.06B	5.50B	5.64B	5.81B	5.24B
Stockholders Equity	11.15B	11.15B	10.94B	10.59B	10.11B	9.27B
Cash Flow
Free Cash Flow	0.00	-491.26M	629.92M	604.44M	625.26M	-2.32B
Operating Cash Flow	0.00	730.91M	1.08B	1.43B	1.57B	837.59M
Investing Cash Flow	0.00	-1.24B	-395.47M	-409.03M	-830.96M	-3.15B
Financing Cash Flow	0.00	-525.74M	-369.96M	-347.89M	-112.74M	1.94B

Sapporo Clinical Laboratory Center, Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1122.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:9776, the sentiment is Neutral. The current price of 1122 is below the 20-day moving average (MA) of 1154.80, above the 50-day MA of 1118.26, and above the 200-day MA of 1027.14, indicating a neutral trend. The MACD of 5.78 indicates Positive momentum. The RSI at 43.90 is Neutral, neither overbought nor oversold. The STOCH value of 5.66 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:9776.

Sapporo Clinical Laboratory Center, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
9776	―	¥3.94B	7.91	―	2.05%	2.23%	12.02%
4694	―	€144.33B	21.67	5.29%	3.28%	5.31%	7.90%
4671	―	¥25.47B	13.45	―	5.06%	1.01%	13.91%
2395	―	¥60.70B	11.99	―	3.43%	27.28%	18.29%
4544	―	¥214.66B	153.81	0.95%	3.32%	2.15%	―
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2385	―	¥4.79B	―	―	2.65%	-6.01%	68.18%